ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
Last trade$6.22
Day change+$0.235 (+3.93%)
Day range$5.92 – $6.37
Volume7,729,159
Market cap$6.36B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$6.36B
Price / earnings
—
Price / book
-5.55×
Price / sales
34.84×
EV / sales
36.93×
EV / EBITDA
-26.17×
Profitability
Earnings per share
-$1.04
Return on assets
-182.09%
Return on equity
96.8%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-0.37×
Current ratio
4.27×
Quick ratio
4.27×
Cash ratio
0.46×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$296.69M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IBRX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$48.84M
$51.24M
$44.21M
$38.29M
$32.06M
$26.43M
$16.52M
$7.55M
Cost of revenue
$1.29M
$298K
$238K
$382K
$177K
$136K
$58K
$0
Gross profit
$47.55M
$50.94M
$43.97M
$37.9M
$31.88M
$26.29M
$16.46M
$7.55M
Selling, general and administrative
$54M
$51.82M
$45.77M
$38.73M
$36.28M
$42.34M
$32.65M
$41.73M
Research and development
$71.54M
$60.82M
$67.99M
$63.86M
$51.23M
$55.24M
$48.23M
$35.22M
Total operating expenses
$125.54M
$112.64M
$113.76M
$102.59M
$87.51M
$97.57M
$80.89M
$76.95M
Operating income
-$77.99M
-$61.7M
-$69.79M
-$64.68M
-$55.63M
-$71.29M
-$64.43M
-$69.4M
Interest expense
-$32.02M
-$31.24M
-$28.46M
-$27.19M
-$27.58M
-$28.88M
-$28.87M
-$37.57M
Income before taxes
-$184.57M
-$230.39M
-$632.79M
-$62.09M
-$67.31M
-$92.31M
-$129.9M
-$59.18M
Income taxes
$0
$0
$9K
-$135K
-$35K
$269K
-$234K
$0
Net income
-$184.57M
-$230.39M
-$632.8M
-$61.96M
-$67.27M
-$92.57M
-$129.67M
-$59.18M
Net income attributable to common shareholders
-$184.55M
-$230.38M
-$632.78M
-$61.94M
-$67.25M
-$92.56M
-$129.65M
-$59.16M
EBITDA
-$74.1M
-$57.29M
-$65.41M
-$60.82M
-$51.68M
-$67.41M
-$60.6M
-$65.26M
Basic earnings per share
-$0.17
-$0.22
-$0.62
-$0.06
-$0.07
-$0.10
-$0.15
-$0.08
Diluted earnings per share
-$0.18
-$0.22
-$0.62
-$0.06
-$0.07
-$0.10
-$0.15
-$0.08
Recent news
Company coverage with links to the original publishers.
ImmunityBio reported a Q3 adjusted loss of 10 cents per share, exceeding estimates of 8 cents, with total revenues of $48.8 million missing consensus of $61 million. While Anktiva revenues grew 53% year-over-year to $48.7 million, they declined 4% sequentially, ending eight quarters of consecutive growth and raising concerns about sales momentum. The FDA expanded Anktiva's label to cover all BCG-unresponsive NMIBC patients, and the company received approval in Israel, supporting future growth prospects.
ImmunityBio (IBRX) reported a quarterly loss of $0.10 per share, missing consensus estimates of $0.08, representing a -25% earnings surprise. Revenue of $48.84 million also missed expectations by 19.6%, though it grew from $32.06 million year-over-year. Despite the miss, the stock has surged 336.1% YTD versus the S&P 500's 7.8% gain. The company maintains a Zacks Rank #2 (Buy) rating based on favorable estimate revision trends ahead of the earnings release.
Agenus (AGEN) reported Q3 2026 earnings of 2 cents per share matching estimates, but revenues of $31.5 million missed consensus expectations of $35 million. Pre-commercial BOT+BAL product revenues declined 6.3% sequentially while non-cash royalties fell 12.4% year-over-year. The stock fell 7.6% following the results. The company received its first-ever drug approvals in Armenia and plans to launch the phase III ROBBIN study in Q1'27, with interim data expected in H2'27.
Sarepta Therapeutics reported Q3 2026 adjusted EPS of 13 cents, missing estimates of 37 cents, though revenues of $381.4M beat expectations. Elevidys gene therapy sales underperformed at $83.5M, while PMO therapies exceeded estimates at $240.3M. The company raised 2026 product revenue guidance to $1.25-$1.3B, supported by strong PMO franchise performance. Stock declined 3.4% after-hours on mixed results.
Zoetis reported Q3 2026 adjusted EPS of $1.75, beating consensus of $1.51, with total revenues of $2.4 billion slightly exceeding expectations. However, U.S. companion animal sales declined 8% due to price sensitivity and competition. The company narrowed 2026 revenue guidance while raising adjusted earnings outlook. Stock rose 7.5% on results but remains down 27.5% year-to-date.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.